HSP-CAR30 with a high proportion of less-differentiated T cells promotes durable responses in refractory CD30+lymphoma


Por: Caballero, AC, Ujaldón-Miró, C, Pujol-Fernández, P, Montserrat-Torres, R, Guardiola-Perello, M, Escudero-López, E, Garcia-Cadenas, I, Esquirol, A, Martino, R, Jara-Bustamante, P, Ezquerra, P, Soria, JM, Iranzo, E, Moreno-Martinez, ME, Riba, M, Sierra, J, Alvarez-Fernández, C, Escribà-Garcia, L and Briones, J

Publicada: 17 abr 2025 Ahead of Print: 1 abr 2025
Resumen:
CD30-directed chimeric antigen receptor T-cell therapy (CART30) has limited efficacy in relapsed or refractory patients with CD30+ lymphoma, with a low proportion of durable responses. We have developed an academic CART30 cell product (HSP-CAR30) by combining strategies to improve performance. HSP-CAR30 targets a proximal epitope within the nonsoluble part of CD30, and the manufacturing process includes a modulation of ex vivo T-cell activation, as well as the addition of interleukin-21 (IL-21) to IL-7 and IL-15 to promote stemness of T cells. We translated HSP-CAR30 to a phase 1 clinical trial of 10 patients with relapsed/refractory classic Hodgkin lymphoma (HL) or CD30+ T-cell non-Hodgkin lymphoma. HSP-CAR30 was mainly composed of memory stem-like (TSCM-like) and central memory (TCM) CAR30+ T cells (87.5% +/- 5%). No dose-limiting toxicities were detected. Six patients had grade 1 cytokine release syndrome, and no patient developed neurotoxicity. The overall response rate was 100%, and 5 of 8 patients with HL achieved complete remission (CR). An additional patient with HL achieved CR after a second HSPCAR30 infusion. Remarkably, 60% of patients have ongoing CR after a mean follow-up of 34 months. CAR30+ T cells at expansion peak had a predominance of TSCM and TCM cells, and CAR30+ T cells remained detectable in 3 of 5 evaluable patients at least 12 months after infusion. Our study shows that selection of the epitope targeting CD30 and ex vivo preservation of less-differentiated memory T cells may enhance the efficacy of CART30 in patients with refractory HL.

Filiaciones:
Caballero, AC:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Ujaldón-Miró, C:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Pujol-Fernández, P:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Montserrat-Torres, R:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Guardiola-Perello, M:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Escudero-López, E:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Garcia-Cadenas, I:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

Esquirol, A:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

Martino, R:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Ezquerra, P:
 Res Inst St Pau Hosp, Unit Genom Complex Dis, Barcelona, Spain

 Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis, Madrid, Spain

 Inst Invest Biomed St Pau, Barcelona, Spain

Soria, JM:
 Res Inst St Pau Hosp, Unit Genom Complex Dis, Barcelona, Spain

 Inst Salud Carlos III, Ctr Biomed Network Res Rare Dis, Madrid, Spain

 Inst Invest Biomed St Pau, Barcelona, Spain

Iranzo, E:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

Moreno-Martinez, ME:
 Inst Invest Biomed St Pau, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Pharm Serv, Barcelona, Spain

Riba, M:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Barcelona, Spain

 Hosp Santa Creu & Sant Pau, Pharm Serv, Barcelona, Spain

Sierra, J:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Barcelona, Spain

Alvarez-Fernández, C:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Escribà-Garcia, L:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain

Briones, J:
 Hosp Santa Creu & Sant Pau, Hematol Serv, Mas Casanovas 90, Barcelona 08041, Spain

 Inst Invest Biomed St Pau, Lab Expt Hematol, Barcelona, Spain

 Josep Carreras Leukemia Res Inst, Barcelona, Spain
ISSN: 00064971





Blood
Editorial
American Society of Hematology, 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA, Estados Unidos America
Tipo de documento: Article
Volumen: 145 Número: 16
Páginas: 1788-1801
WOS Id: 001474255500001
ID de PubMed: 39841453

MÉTRICAS